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 The hedgehog (Hh) signaling pathway is activated in many types of cancer and 
therefore presents an attractive target for new anticancer agents. In the studies described 
here I demonstrate how mebendazole (MBZ), a benzimidazole with a long history of safe 
use against nematode infestations and hydatid disease, potently inhibited Hh signaling 
and slowed the growth of Hh-driven human medulloblastoma cells at clinically attainable 
concentrations. As an antiparasitic, MBZ avidly binds nematode tubulin and causes 
inhibition of intestinal microtubule synthesis. In human cells, MBZ suppressed the 
formation of the primary cilium, a microtubule-based organelle that functions as a 
signaling hub for Hh pathway activation. The inhibition of Hh signaling by MBZ was 
unaffected by mutants in the gene that encodes the Hh pathway signaling protein SMO, 
which are selectively propagated in cell clones that survive treatment with the Hh 
inhibitor vismodegib. Combination of FDA approved Hh inhibitor vismodegib and MBZ 
resulted in additive Hh signaling inhibition. Because MBZ can be safely administered to 
adults and children at high doses over extended time periods, I propose that MBZ could 
be rapidly repurposed and clinically tested as a prospective therapeutic agent for the 
many tumors that are dependent on Hh signaling.  
One important genetic regulator of Hedgehog signaling is the tumor suppressor 
PTCH1. In addition to my studies of the canonical Hedgehog pathway and its inhibition 
by MBZ, I have also investigated a non-canonical pathway mediated by a novel PTCH1 
homolog recently identified in our lab.  I present evidence that this new gene, PTCH53, 
functions both in the canonical Hedgehog pathway and in a noncanonical Hh pathway 
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Chapter 1: Background and relevant literature  
             
1.1. Introduction 
Activation of the hedgehog (Hh) signaling pathway is required for developmental 
morphogenesis and is frequently observed in human cancers (1, 2). Canonical Hh signals 
are initiated by the interaction of Hh ligands with the receptor PTCH1. In the unbound 
state, PTCH1 prevents SMO activation in the primary cilium, an organelle required for 
the transduction of various chemical and mechanical signals (3). In the presence of 
ligand, PTCH1 disappears from the cilium and SMO activates downstream effectors, 
including the GLI family of transcription factors (4).  Several types of cancer, including 
basal cell carcinoma and medulloblastoma, are frequently caused by germline or somatic 
mutations in PTCH1 or by less common alterations within the pathway that lead to 
constitutive signaling by SMO (1, 2). Alternative modes of Hh pathway activation in 
some of the most common types of cancer are suggested by the widespread presence of 
Hh ligands and evidence of elevated GLI activity in many tumors that lack pathway-
activating mutations (5, 6). Greater understanding and targeting of the canonical and 
noncanonical hedgehog pathways can lead to improved cancer therapies.  
1.2. Canonical and noncanonical hedgehog pathway 
1.2.1.  Discovery 
The Hh gene was first discovered in 1980 by Christiane Nusslein-Volhard and 
Eric Wieschaus in a screen of mutant Drosophila and was named after the distinctive 
embryonic cuticle patterning in mutant flies (7). Hh was subsequently found to be a 
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secreted ligand that mediates developmental patterning. Hh signaling is evolutionarily 
conserved between Drosophila and higher organisms including humans. The vertebrate 
homologs of Hh ligand were being identified in 1993 (8). In contrast to Drosophila, 
vertebrates express three separate isoforms of the Hh protein including Sonic hedgehog 
(Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh) (9). Each form shows a unique 
spatial and temporal distribution patterns and modulates distinct cellular responses (10). 
The downstream signaling of the Hh pathway has evolved from the single downstream 
transcription factor Cubitus interruptus (Ci) found in Drosophila to several human 
homologs known as the Gli family of transcription factors (11). In humans, the Hh family 
of proteins has proven to be a key mediator both in embryonic development and 
maintenance of continuously renewing tissues including adult stem cells (12).  
 The Hh pathway has shown to have a diverse and complex role in multiple 
aspects of embryonic development. Hh ligands control cell survival, proliferation, fate, 
patterning, and differentiation (13). Embryonic cells that secrete Hh are distinct from the 
cells that respond to it (14). Hh-responsive cells can either be adjacent to or at a 
significant distance from the Hh-secreteing cells. Hh can regulate cell numbers and fate 
in the brain, spinal cord, limbs and in many internal organs including the heart (9). The 
importance of Hh ligands is highlighted by the defects that occur following alterations in 
the signaling pathway during development. Outcomes related to Hh pathway inhibition 
include brain, facial and other midline defects including cyclopia, microencephaly, 
holoprosencephaly, absent nose, or cleft pallet (15-17). The effect of Hh ligands on cell 
fate is often translated through differences in signal strength and duration which modulate 
the response. These processes take place in close association with the developmental 
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regulation of bone morphogenetic protein, parathyroid hormones and retinoid signaling 
(18-20). 
 Although the role of Hh signaling is diminished after embryonic development, a 
modest level of expression in adulthood is critical to the regulation of tissue homeostasis. 
Elevated Hh activity is observed in renewable adult tissues including gut epithelium, 
pulmonary epithelium, prostate epithelium, and exocrine pancreas. Hh activity is also 
reactivated at damaged sites requiring tissue repair (21, 22). Additionally, stem and 
progenitor cell maintenance in the brain, epithelia, prostate, lung and mammary glands is 
regulated by Hh (12).  
 The generation of functionally mature Hh ligand begins with cleavage of a 
precursor protein to expose the active signaling domain (HhNp). Cholesterol is then 
transferred to the C terminal domain of the Hh polypeptide, this modification drives the 
association of the Hh protein with the plasma membrane (23). In the final processing 
step, a palmitoyl moiety is added to the N terminus by acetylation from the Rasp enzyme 
(24). Once processing is completed, fully active Hh ligand can be secreted from the cell.   
1.2.2. The canonical hedgehog signaling pathway 
In the absence of activation by extracellular ligand, the Hh pathway is 
constitutively suppressed by the 12 spanning transmembrane protein Patched 1 
(PTCH1). PTCH1 sequesters the seven transmembrane spanning protein Smoothened 
(SMO) that is responsible for activating all downstream signaling (Fig 1.1.). SMO is a 
functional G-protein-coupled receptor (GPCR) that aggregates around the primary cilia 
and whose activation is in part regulated by phosphorylation (25). The Hh signaling 
cascade is initiated by the binding of sonic hedgehog (Shh) ligand to PTCH1 on the cell 
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surface. This binding induces internalization of the bound proteins and degradation by 
lysosomes. Once de-repressed, SMO is able to dissociate the complex of suppressor of 
fused (SUFU) and glioma associated oncogene homologue (GLI) complex. The GLI 
family of zinc finger transcription factors includes GLI1 and GLI2 that are typically 
activators of the Hh pathway and GLI3 that is classically a repressor and is only active 
when Hh is unbound. When SMO is active the GLI complex undergoes nuclear 
translocation and regulates a large set of target genes.  
Hh pathway activation results in increased expression of GLI1, GLI2, and PTCH1 
transcripts and proteins. GLI1 transcripts are a useful readout of pathway activity and 
are frequently used as a quantitative marker for Hh pathway activation in cancers. A 
variety of feedback loops tightly control duration and amplitude of the Hh response, 
which is why both suppressors (PTCH1) and activators (GLI1, GLI2) of the pathway are 
transcriptionally upregulated. Other downstream genes activated by Hh classically fall 
into three categories: suppressors of apoptosis (eg. BCL-2), promoters of angiogenesis 
(eg. angiopoietin-1, angiopoietin-2, n-myc, BMI1, VEGF), and promoters of metastasis 
(upregulation of Snail and suppression of E-cadeherin), but these are cell type dependent 
(17, 26-28). The canonical Hh pathway has proven to be an incredibly important for 
both development and homeostasis of progenitor cells in adulthood. The canonical 
pathway is defined as all of the processes that are regulated through the transcriptional 





Figure 1.1. Hedgehog signaling (29) 
The Hedgehog pathway is normally regulated through a cascade of primarily inhibitory 
signals. Depending on the tissue and developmental stage, one of 3 mammalian 
Hedgehog (Hh) ligands (Sonic Hh, Indian Hh, or Desert Hh) binds to cell surface 
PTCH1. Ligand binding to PTCH1 relieves PTCH1 inhibition of the critical activator of 
Hedgehog signaling, SMO. PTCH1 deficiency, found in the majority of BCC and about 
30% of medulloblastoma, is associated with constitutive, ligand-independent activation 
of SMO. In mammalian cells, de-repression of SMO is associated with its translocation 
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from internal vesicles to the cell membrane cilium (not shown). Active SMO signals 
downstream through an intermediary Sufu, promoting the release of Gli family 
transcription factors, which can then translocate to the nucleus to affect gene 
transcription. There are multiple Gli proteins whose functions are somewhat cell type 
dependent; in general, Gli2 seems to be a particularly strong activator of downstream 
gene transcription (along with Gli1), while Gli3 is inhibitory in most contexts. Pathway 
activation and release from Sufu can lead to proteosomal degradation of Gli3 and to 
preferential nuclear translocation of Gli1 and Gli2, which activate transcription of 
multiple target genes, including key regulators of the Hedgehog pathway, notably Gli1 




1.2.3.  Primary cilia 
Primary cilia are stationary microtubule based organelles that extend from the cell 
surface and mediate various extracellular signals to the cell through the intraflagellar 
transport system. Primary cilia, unlike the cilia of cells lining the human airway, are 
non-motile extensions from the plasma membrane. Primary cilia are expressed in 
vertebrates in various tissues. Their function is to detect changes in the extracellular 
environment. The primary cilium is the point of localization for signaling proteins in the 
Hh pathway, and is therefore considered the center for mediating most Hh signaling. 
Dysfunctional primary cilia have been linked to several human development disorders 
that resemble conditions caused by genetic defects in Hh signaling. For example, the 
human limb abnormality polydactyly has been linked to disrupted Hh signaling and also 
is seen in patients with Bardet-Biedl syndrome and Meckel-Gruber syndrome, both of 
which are characterized by defective ciliary function (30, 31). 
The primary cilium is a dynamic organelle as it extends during interphase and  is 
reabsorbed during cell cycle progression (32). This process is tightly linked to the cell 
cycle because the microtubule basal body that form the primary cilia’s base contains 
centrioles that move away from the cell surface to a spindle pole during mitosis. During 
interphase, the extension of the primary cilium is initiated by centrioles moving to the 
plasma membrane and the aggregation of pericentriolar material around them. These 
structures promote microtubule polymerization (33). Tubulin polymerizes to form the 
core of the primary cilium, known as the ciliary axoneme. Between the ciliary axoneme 
and the basal body exist terminal plates, transition fibers, and condensed lipids. All of 
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these components are believed to contribute to the regulation of bidirectional protein 
trafficking between the cilia and the cytoplasm (34).  
It is well understood that the major canonical hedgehog pathway components, 
PTCH1, SMO, SUFU, and GLI family of transcription factors, localize to primary cilia 
at various times (4, 35). The exact sequence of events following Hh activation remains 
to be definitively described.  
The key regulatory feature of the canonical Hedgehog pathway is the negative 
regulation of SMO by PTCH1. Initially, it was believed that the inhibition of SMO by 
PTCH1 was a result of a direct physical interaction between the two proteins, but new 
data support a model in which PTCH1 regulates SMO activity via its ability to localize 
to the primary cilium. One theory suggests that PTCH1 resides in the primary cilia and 
excludes SMO until Hh binding activates a translocation of PTCH1 to the base of the 
primary cilia allowing SMO to enter and de-repressing SMO’s ability activate 
downstream Hh signaling (36). PTCH1 may regulate SMO trafficking to and from the 
cilia by modulation of cholesterol levels within the cilium (37). Mutational analysis 
suggests that intraflagellar transport functions downstream of activated SMO and 
upstream of the Gli family of transcription factors, thereby defining the critical range in 
which primary cilia mediates Hh signaling (38). In support of this hypothesis, mice with 
mutations in basal body proteins Ofd1, Mks1, and Ftm exhibit abrogated cilia formation 
and these mutations also confer suppressed Hh signaling in response to ligand (39-41). 
Current evidence thus indicates that functional primary cilia are required for mediating 
competent downstream Hh pathway signaling. 
1.2.4. Noncanonical hedgehog signaling pathways 
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A noncanonical Hh signaling pathway is a loose definition for any pathway that 
involves the upstream ligand and receptor components, but does not appear to involve 
downstream activation of the GLI proteins (42). Though poorly understood, these 
pathways have been proposed to fall into two distinct classes: a type 1 noncanonical 
pathway operates through PTCH1 independently of the activity of SMO or GLI, while a 
type 2 pathway is mediated through SMO activity unrelated to GLI signaling (43). 
Hh signaling suppresses apoptosis through multiple mechanisms that involve both 
canonical and noncanonical pathways. Canonical regulation of programmed cell death is 
controlled by GLI-mediated expression of pro-survival genes such as BCL-2 and 
activation of the survival kinase AKT (44, 45). In a poorly understood noncanonical 
pathway, PTCH1 overexpression induces apoptosis that cannot be rescued by 
overexpression of SMO, while PTCH1 knockdown increases cell survival (46, 47). 
Direct regulation of apoptosis by PTCH1 is mediated through its C-terminal domain.  
Canonical Hh signaling has shown to be an important driver of proliferation by 
through expression of n-myc and cyclin D1 (48, 49). However, in the absence of Shh 
ligand, PTCH1 binds to phosphorylated Cyclin B1 and inhibits mitosis in a 
noncanonical fashion (50). 
Type 2 noncanonical signaling is by definition mediated through SMO, 
independently of downstream GLI1. When stimulated by Hh ligand, SMO activates both 
GTPase RhoA and Rac1 by releasing Tiam1 that it normally sequesters (51). SMO’s 
activation of RhoA causes the immediate formation of actin stress fibers within minutes 
and tubulogenesis within hours (52). SMO knockout cell lines are incapable of activation 
of RhoA and Rac1 and fibroblast migration is only possible in cells with functional 
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SMO (53). Shh ligand can also activate several Src family kinase to regulate axon 
guidance through SMO. Studies have shown Shh stimulated cell migration and 
cytoskeletal rearrangements are mediated through SMOs upregulation of the arachidonic 
acid metabolite leukotriene that induces lamellipodia formation and neurite projections 
(54, 55). 
1.2.5. Adult progenitor  and stem cells 
The formation and maintenance of adult hematopoietic stem cells relies on the 
presence of Hh signaling. Accordingly, both hematopoiesis and vasculogenesis are 
inhibited  in mouse embryos that lack Hh signaling (56). Similar to development, each of 
the three isoforms of Hh has a functionally unique role in adult progenitor cell 
homeostasis. In stromal cells after a bone marrow transplant, hematopoeitic regeneration 
is dependent upon Ihh overexpression (57). Expansion of primitive hematopoietic stem 
cells can be successfully achieved by activation of the Hh pathway (58).  
Hh ligands control the proliferation, specification, and differentiation of 
embryonic neural precursors, and are required for the maintenance of adult quiescent 
neural stem cells. A well-defined role of Shh in differentiation is its expression from 
Purkinje cells during cerebellar development, during which ligand  induces the rapid 
proliferation of granule cell precursors (59).  
Deregulation of the Hh pathway within stem cell niches has been shown to 
contribute to a diverse range of cancers and disorders including Gorlin syndrome and 
Greig cephalopolysyndactyly syndrome (60). A hallmark of these cancers is the 
activation of the pathway without the presence of any Hh ligand. However, other 
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cancers appear to exhibit ligand dependency including gastrointestinal tumors, gliomas, 
hematological malignancies and prostate cancer (5, 21, 61, 62). 
1.3. Hedgehog and cancer 
1.3.1. Basal cell carcinoma and nevoid basal cell carcinoma 
Basal cell carcinomas (BCC) represent a third of all cancers diagnosed every year 
in America, with a lifetime risk of 1 in 6 overall and 1 in 3 for Caucasians (63). Nearly all 
sporadic BCC are driven by aberrant Hh signaling (64). 90% of cases are driven by 
inactivating mutations of the Hh pathway inhibitor PTCH1 and the other 10% are driven 
by activating mutations in the Hh pathway activator SMO. Furthermore, loss of p53 
promotes BCC development in part by increasing expression of SMO (65). This finding is 
supported by preclinical in vivo models where homozygous loss of TP53 accelerates 
formation of medulloblastoma in Ptch1
+/-
 mice (66).  
Mutations that affect the Hh pathway also play a critical role in hereditary cancer.  
Nevoid basal cell carcinoma (NBCC), commonly known as Gorlin syndrome, is an 
autosomal dominant inherited disease that is characterized by multiple cutaneous basal 
cell carcinomas. Medulloblastoma or rhabdomyasaroma are also associated with this 
syndrome.(64). The disease is caused by inactivating mutations in the PTCH1 gene 
rendering it unable to inhibit SMO (67). In vivo models for NBCC use mice with Ptch1
+/- 
backgrounds and display multiple phenotypes representative of patients including a 25% 
occurrence of medulloblastoma (60, 68, 69). When Ptch1
+/- 
mice are crossed with Tp53 
knockout mice the rate of tumor occurrence increases to 100% with significant 




Medulloblastoma is the most common malignant brain tumor in children and the 
leading cancer mortality in children (71). There are four distinct molecular subgroups of 
medulloblastomas, defined by their mutational profile and patterns of gene expression. 
Group 1 medulloblastomas are driven by the Sonic Hedgehog (Shh) pathway and 
constitute about a third of diagnoses. These tumors typically respond relatively well to 
conventional treatment. The well-defined role of Shh signaling in cerebellar 
development and initiation of rapid granule cell precursor proliferation creates a clear 
link between Hh pathway activation and transformation of the granule cell precursors 
leading to medulloblastoma (72). Interestingly, there is a similar gene expression pattern 
in group 1 medulloblastomas and granule neuron progenitor cells (73). Oncogenesis is 
believed to occur when actived Hh pathway in granule neuron progenitor cells fails to 
become normally down-regulated during terminal cell differentiation. Of the group 1 
category of medulloblastomas, half are associated with a loss or mutation of either 
PTCH1 or SUFU, or a gain of function SMO mutation, with PTCH1 inactivation being 
the most common (74). Thus, there is a subset of medulloblastomas that are exhibit Hh 
pathway overactivation without a representative Hh driver mutation, highlighting our 






1.3.3.  A broad role for hedgehog pathway activation in human cancers 
Many cancers exhibit evidence of activated canonical Hh signaling in the 
apparent absence of pathway mutations. GLI1 overexpression has been identified in 
glioblastoma and childhood sarcoma (75, 76). and Shh  ligand and elevated GLI 
expression have been detected in melanomas, lung cancers, ovarian cancers, 
adrenocortical cancers and colorectal cancers (5, 6, 77-80). Several cancers that do not 
appear to harbor Hh signaling mutations have shown sensitivity to SMO inhibitors in 
both in vitro and in vivo  (81). In total, as many as 25% of all human tumors may depend 
on Hh pathway activity for growth (82). The hedgehog pathway can be activated by Shh 
ligand in both paracrine and autocrine dependent manners. SMO inhibitors showed a 
successful survival response in a pancreatic cancer mouse model along with depletion of 
tumor associated stromal tissue (83). In leukemia, GLI1 has been shown to function 
autonomously to promote cell survival and studies indicate it functions independently of 
Shh and SMO (84).  
Several in vitro models are able to replicate Hh pathway activation usually only 
seen in patients or in vivo. The Hh pathway has been identified as a driver of proliferation 
in malignant pleural mesothelioma cells and as a key component for tumor maintenance 









) all have shown dependence on Hh pathway 
components (86).  
1.4. A homolog of PTCH1 
14 
 
The human genome contains as many as 10 homologs of PTCH1. The roles of 
these genes in the regulation of the Hh pathway are unknown.  Our laboratory recently 
identified a PTCH1 homolog that is transcriptionally regulated by p53, and was 
accordingly designated PTCH53 (Fig 1.2.A).  
More than 50% of human tumors contain either a mutation of deletion of TP53 
(87). p53 is a major tumor suppressor that functions by regulating cell cycle and 
apoptosis (88). More than 500 p53 binding sites have been identified in the human 
genome, however the entirety of its tumor suppressor mechanism is yet to be identified 
(89). PTCH53 transcription was dependent on functional TP53 expression in a diverse 
range of human tumor types according to the global gene expression data of the cancer 
cell line encyclopedia.   
Inducible overexpression and knockdown of PTCH53 in immortalized human 
retinal pigment epithelial (hRPE1) cells showed a greater than two fold induction and 
suppression respectively of 15 interferon-stimulated genes typically activated by type 1 
interferon (Fig 1.2.B and 1.2.C). PTCH53 plays a potential role in GLI suppression, but 
appears to be a significant regulator of interferon-stimulated genes. While the role of 
ligand in the process is unclear, it is possible that PTCH53 thus functions in a 




Figure 1.2. PTCH53 regulates interferon stimulated genes (Jon Chung et al., 
unpublished) 
(A) PTCH53 expression is induced by p53. Predicted primary structure for PTCH53 and 
PTCH1.  Black bars indicate transmembrane domains.  SSD = sterol-sensing domain.  
The two regions of homology characteristic of Patched proteins are shaded in orange. The 
% similarity (% identity) within these regions is indicated. (B) Regulation of interferon 
stimulated genes by PTCH53. hTERT-RPE1 cells with doxycycline-inducible PTCH53 
cDNA or a doxycycline-inducible PTCH53 shRNA were grown in low serum media for 
48 h prior to induction with doxycycline for 48 h. RNA was collected before and after 
doxycycline treatment. PTCH53 RNA expression was measured by qPCR.  Individual 
genes and their changes in expression after doxycycline treatment are shown. (C) In an 
independent experiment that replicated the conditions for the microarray experiment, 





1.5. Hedgehog Inhibitors 
1.5.1. Cyclopamine 
Cyclopia is a birth defect characterized by an undivided forebrain and the absence 
of median facial structures. An endemic of cylopia occurred among the western United 
States in sheep herds during the 1950’s (90, 91). The cause was determined to be 
consumption of Veratrum californicum, a lily indigenous to subalpine meadows. The lily 
contains the teratogenic steroidal alkaloid cyclopamine that was eventually proven to be a 
naturally occurring potent Hh inhibitor (92). This was a key finding as it proved that the 
Hh pathway contained druggable targets. The clinical applicability of Hh inhibition 
became apparent when cyclopamine was shown to reverse the oncogenic effect of both 
the inactivating mutation of PTCH1 and the activating mutation in SMO (93).  
Cyclopamine acts as a Hh antagonist by binding to the heptahelical bundle of 
SMO and thereby stabilizing the protein in an inactive conformation (94). Inhibition of 
SMO causes suppression of GLI transcriptional activity.  Although it was proposed as a 
potential anticancer drug, cyclopamine never went to clinical trial for treatment of any Hh 
driven cancers due to its many off-target effects such as induction of neuronal-nitric 
oxide synthase and neutral sphingomyelin phosphodiesterase 3 (95). Instead, a 
cyclopamine derivative known as Saridegib or IPI-926 completed Phase 1 and went to a 





In 2000, a growing body of evidence supported the role of Hh signaling in many 
cancers. The discovery that the small molecule cyclopamine could inhibit Hh signaling 
drove biotech and pharmaceutical companies to begin developing their own inhibitors. 
The first successful Hh antagonist brought to clinical trials in 2007 was vismodegib 
(GDC-0449) developed by Genentech. Vismodegib was structurally unrelated to 
cyclopamine, but shared the same effective strategy of binding to the extracellular 
domain of SMO in tumors with active Hh (96). However, vismodegib possessed a higher 
affinity and specificity to SMO than cyclopamine. This affinity was achieved through 
screening multiple candidates in an Hh reporter assay.  In this assay, C3H10T1/2 mouse 
fibroblasts cells were transfected with Gli1-luciferase reporters and treated with media 
conditioned with ShhN, a truncated form of the Shh ligand bearing an identical amino 
acid sequence but lacking the cholesterol modification. Among the many compounds 
tested vismodegib resulted in a 20-fold increase in affinity compared to cyclopamine with 
an IC50 of 13 nM (the IC50 of cyclopamine is 300 nM) (97). In Hh-dependent 
medulloblastoma flank allografts generated from Ptch
+/-
 mice, complete regression was 
achieved by vismodegib at doses as low as 12.5mg/kg in vivo .  
Vismodegib (marketed as Erivedge) became the first SMO antagonist to be FDA 
approved for clinical use in 2012 in treatment of locally advanced and metastatic basal 
cell carcinomas (98). It is currently being tested for use in adults and children with many 
diverse types of tumors. There are currently 48 clinical trials involving vismodegib, the 
majority of which are ongoing.  Many tumors are being tested, including 
medulloblastomas and gliomas, which are often refractory to conventional therapies (99).  
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Due to the unique inherited genetic driver of the NBCC, patients often aware of 
their disease prior to its first emergence or manifestation. The current standard of 
treatment is palliative care and includes repeated surgery to reduce tumor burden. 
Clinical trials are currently ongoing for attempting daily dosing of vismodegib as a 
preventative agent for these patients; however concerns of compliance have been raised 
due to its harsh side effects. Continuous treatment of low-toxicity Hh inhibitors has been 
proposed as a possible treatment for these patients in order to decrease chances of tumor 
emergence. 
When used as a monotherapy, vismodegib is associated with adverse effects that 
include fatigue, vomiting, weight loss, decreased appetite, dysgeusia, dehydration, and 
muscle spasm (100). Such low-grade toxicities have contributed to treatment 
discontinuation and appear to be potentially problematic when vismodegib is combined 
with conventional agents (101).  When used to treat a patient with metastatic 
medulloblastoma, vismodegib caused a response that was impressive but transient (Fig 
1.3) (102). Genetic analysis of the vismodegib resistant subclones has shown they harbor 
SMO mutations (Smo D477G) that blocks vismodegib binding and subsequent Hh 
inhibition (103).  Recurrent tumors that harbor a SMO mutation that confers drug 
resistance was also seen in a case report of BCC (103). Selection for SMO-mutant tumor 
cell populations can similarly be caused by vismodegib therapy in mouse models of 
medulloblastoma (103).  Alternative strategies to inhibit Hh signaling have been explored 





Figure 1.3. Transient response of a disseminated medulloblastoma to vismodegib 
treatment (102) 
Whole-body projections from 18 F-fluorodeoxyglucose (FDG)–PET scans are 
shown. Panel A shows the pretreatment scan; Panel B, the repeat scan after 2 months of 
therapy with the hedgehog pathway inhibitor vismodegib; and Panel C, the repeat scan 




1.5.3. Itraconazole and Arsenic Trioxide 
Drug development is both time and resource intensive with no guarantee of 
success. Even if a small molecule performs well in model systems, the chances of it 
maintaining its efficacy in patients without severe complications and completing clinical 
trials with FDA approval remains only 13% (105). The successful treatment of Hh driven 
cancers in vitro and in vivo by SMO inhibitors created a push to not only develop new Hh 
antagonists, but also to repurpose molecules that were already FDA approved. In 2006, 
James Kim screened 2,400 FDA approved or post-phase I trials drugs for efficacy against 
Hh signaling (106). The model used for screening had been previously established. 
ShhLight II cells are a mouse fibroblast cell line (3T3) with a stably integrated Gli-
activated firefly luciferase (Gli-luc) reporter construct and a constitutive renilla luciferase 
(TK-renilla) reporter (93). The assay is performed by stimulating cells with Shh ligand to 
activate Gli transcription and measuring the increase in luciferase expression. The screen 
was designed to identify compounds that reduced luciferase activity, indicating inhibition 
of GLI transcription by Hh ligand. In evaluating therapeutic plausibility of all compounds 
identified by the screen, several factors were considered. These included whether the 
compound had previously received FDA approval for use in humans, whether Hh 
inhibition was could be observed at physiologically relevant serum concentrations, and 
whether the drug exhibited general toxicity. Of the 2,400 drugs screened by Dr. Kim’s 
group, several showed activity against Hh at a dose range that was attainable in humans. 
One of these drugs was itraconazole, an FDA-approved, nontoxic drug that is a 
commonly prescribed antifungal, that can be administered systemically for months. 
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Itraconazole is a broad spectrum triazole antifungal used against Aspergillosis, 
Candidiasis, Cryptococcosis, Blastomycosis, Sportotrichosis, Histoplasmosis, and 
Onychomycosis. As an antifungal agent, the mechanism of action of itraconazole is 
inhibition of cytochrome P450 lanosterol 14-α-demeylase (14LDM).  Itraconazole 
coordinates the heme Fe
2+
 in the active site of 14LDM. This coordination blocks the 
demethylation of lanosterols into ergosterols (107). In fungi, ergosterols perform the 
same basic function as cholesterol in mammals and are a critical component for cell 
membranes. A human homolog of 14LDM is critical for cholesterol synthesis; 
itraconazole has a preference for inhibiting the fungal form (108). However, high doses 
of itraconazole have shown to decrease cholesterol in humans (109). In ShhN-stimulated 
ShhLight II cells, itraconazole functions as a potent SMO antagonist with an IC50 of 800 
nM. Interestingly, itraconazole acts on SMO at a distinct target site from cyclopamine 
and vismodegib. Follow up in vivo studies demonstrated that itraconazole could 
successfully inhibited growth of Hh-dependent flank models of medulloblastoma and 
BCC.  
In addition to itraconazole, the screen by Kim et al. also identified several 
microtubule inhibitors.  Vinblastine, vincristine, and paclitaxel were some of the vinca 
alkaloid derivatives that consistently performed as Hh antagonists at pharmacologically 
attainable concentrations. Cancers that respond to Hh antagonists typically require long 
courses of therapy (6, 110, 111). The microtubule inhibitors identified in the screen, 
while showing potential efficacy against the Hh pathway, were also potent mitosis 
inhibitors and were too toxic to be a considered long term therapy and therefore no 
further follow up studies were performed.   
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As of 2013, Arsenic trioxide (ATO) is the standard of treatment for concurrent 
chemotherapy of acute promyelocytic leukemia (APL), in addition to an approved 
combination therapy with all-trans retinoic acid (ATRA) against certain leukemias when 
unresponsive to first line therapies (112). The treatment carries significant risk due to 
known toxicities of arsenic poisoning, however its ability to induce apoptosis in 
cancerous cells under certain circumstances justify the treatment (113). While 
investigating ATO’s effects, it was noted that pregnant mice treated with ATO had a 
number of embryonic development problems consistent with Hh inhibition such as 
improper axial skeleton and limb development. Using the same screening assay that was 
used to identify itraconazole, investigators found that ATO inhibited Hh signaling with 
an IC50 of 700 nM.  
Unlike the first generation of Hh inhibitors, ATO does not target SMO. Instead, it 
inhibits trafficking of GLI2 to the primary cilia to suppress of Hh signaling (114). Like 
itraconazole, ATO suppressed growth in vivo against the flank Hh-driven 
medulloblastoma model.   
ATO has been reported to have significant side effects. A quarter of patients 
undergoing APL induction therapy with ATO and/or ATRA will experience 
differentiation syndrome, a potentially fatal compilation caused by leukemic blasts 
undergoing cellular migration, endothelial activation, and release of interleukin and 
vascular factors (115). It is life threatening side effect that can lead to tissue damage and 
acute renal failure. ATO treatment can also induce a variety of heart related issues 
including atrioventricular block, QTc prolongation, and torsades de pointes-type 
arrhythmias (116).  Other adverse effects from ATO treatment include peripheral 
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neuropathy, musculoskeletal pain, leukocytosis, and hepatitc toxicity (117). For these 
reasons, patients receiving ATO should be closely monitored. 
Itraconazole and ATO can be combined for an additive effect against Hh 
signaling. Each drug, both independently and together, showed efficacy against all known 
vismodegib and cyclopamine resistant forms of SMO (104). While neither compound 
was able to completely suppress growth like vismodegib, they were able to both 
significant delay tumor growth alone and with greater efficacy together. Transcripts from 
the tumors were analyzed by qRT-PCR and showed that all Hh antagonists caused 
reduced GLI1 levels by at least 40%. As expected, the degree of GLI1 inhibition was 
found to correlate with treatment response in the medulloblastoma and BCC model. 
Lastly, all compounds and combinations were tested in an orthotopic Hh-driven 
vismodegib resistant (Smo
D477G
) medulloblastoma. Only itraconazole and ATO showed 
efficacy and elicited a greater response in combination. This was the first evidence that 
both compounds could successfully pass the blood brain barrier.  
While neither itraconazole nor ATO has the same efficacy of vismodegib against 
Hh driven cancers, they can contribute to an improved therapy by targeting separate 
components of the Hh pathway. While vismodegib resistant SMO mutations have 
emerged from treatment, combination therapy decreases the odds of a single clone with 
simultaneous compensatory mechanisms against both treatments. Therefore, 
simultaneously targeting both SMO and GLI2 transcription factor may provide an 
improved therapeutic response. Combination therapy involving vismodegib also provides 
the possibility of achieving the same amount of Hh inhibition while decreasing the 
vismodegib dosage to reduce unwanted side effects. However, both itraconazole and 
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ATO have their limitations. While clinical trials are ongoing for itraconazole, it has 
shown modest effect in castration-resistant prostate cancer and metastatic nonsquamous 
non-small-cell lung cancer. However, its effect on cancers in patients with clear Hh 
dependence has not yet been determined (118, 119). In addition, ATO has well 
characterized harmful side effects that need to be considered before pursuing as a 
therapy.  
1.5.4. Drugs in the pipeline 
As Hh pathway inhibition grows as a promising therapeutic strategy, novel 
inhibitors continue to be developed. Over 75 new inhibitors have been patented or are 
currently in the pipeline of various pharmaceutical companies (96). Although vismodegib 
is only FDA-approved for BCC, clinical trials are ongoing to test its efficacy in a variety 
of other of Hh-driven cancers. In addition, seven new Hh inhibitors have entered phase I 
and II clinical trials. The current Phase I or II clinical trial candidates includes IPI-926 
(Infinity Pharm), LDE225 (Novartis), LEQ506 (Novartis), PF-04449913 (Pfizer), TAK-
441 (Millennium Pharm), BMS833923 (Bristol Myers Squibb), and LY2940680 (Eli 
Lilly) (120). Currently, the only target for Phase I and II hedgehog inhibitors is SMO, 
highlighting the need for alternate Hh pathway targets to decrease the potential for 
resistance emerging through SMO-binding mutations.  
The proposed mechanisms for the dozens of preclinical Hh inhibitor candidates 
are much more diverse. These compounds target a range of components in the Hh 
pathway including Shh, SMO, GLI1 and GLI2. However, there is no guarantee that any 
of these will successfully make it to clinic. It is therefore worthwhile to further explore 
currently FDA approved compounds that may provide novel target for Hh therapy. 
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1.6. Mebendazole  
1.6.1. Anthelminthic Properties 
Helminth infections occur in 1.5 billion people worldwide, over 20% of the 
world’s population (121). To address the endemic, there has been continuous research 
into the development and characterization of anthelmintic therapy for the last 60 years. 
As a result of this research effort, the current generation of anthelminthic compounds is 
extremely safe and effective in humans.  
Mebendazole (methyl N-[6-(benzoly)-1H-benzamidazol-2-yl] carbamate; MBZ) 
is a US Food and Drug Administration approved anthelminthic that has been used to treat 
parasitic worms since 1968. MBZ is one of six antiparasitic drugs of the benzimidazole 
class that also includes albendazole (ABZ), fenbendazole (FBZ), and thibendazole 
(TBZ). While all benzimidazoles are used in veterinary medicine, only ABZ, TBZ, and 
MBZ are approved for use in humans (122). 
MBZ’s mechanism of action against nematode infestation was first proposed in 
1975. MBZ functions in parasites by binding to the colchicine-sensitive site in free β-
tubulin, inhibiting it from being polymerized into microtubules (123). Intracellular 
transport processes that are dependent on the formation of cytoplasmic microtubules are 
also impaired in the parasite. The immediate result is impaired uptake of glucose by 
intestinal cells in larval and adult parasites. Without glucose uptake the parasite soon 
depletes its glycogen stores. This results in a series of downstream effects including the 
degenerative change of the mitochondria germinal layer and lysosome release which 
ultimately lead to an interruption of ATP production. Without any available energy the 
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parasite is immobilized and eventually dies. All benzimidazoles share the same proposed 
mechanism against nematode infections (124).  
1.6.2. Safety  
MBZ is often prescribed in humans due to its minimal side effects and broad 
spectrum anthelmintic abilities. It is effective against roundworm, whipworm, 
threadworm, tapeworm and hookworm. Complete elimination of the parasite often can be 
accomplished with a single 500 mg dose, however a follow up dosage two weeks later is 
typically recommended. Due to its remarkable safety and tolerability MBZ remains 
among the most widely used drugs in infected adults, including pregnant women and 
children. The difference in MBZs effect between species is due to a difference in 
stability. The rate of dissociation of MBZ from nematode tubulin is an order of 
magnitude lower than from human tubulin (125).  
Mebendazole has a long track record of safety, having been used against parasitic 
infection for over 40 years. There are multiple documented cases of MBZ serving as long 
term chemotherapy for echinococcosis (hydatid disease) with no adverse side effects 
even after more than 13 years of daily therapy (48 mg/kg/day) (126). Doses as high as 
200 mg/kg/day have been safely and effectively administered for up to 48 weeks for the 
treatment of internal hydatid cysts (127, 128). Unlike many therapeutic agents, MBZ has 
also been proven to accumulate to therapeutically relevant doses in the cerebrospinal 
fluid when treating helminth infection in the central nervous system, justifying possible 
MBZ therapy for diseases that affect the brain (127). The only significant side effect of 
these high, chronic doses is bone marrow suppression that has only been observed in 
fewer than 5% of patients.  Case reports suggest that this adverse effect is associated with 
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increased therapeutic effect, and is therefore probably caused by higher blood levels of 
MBZ in these patients. In supportive clinical settings, this untoward effect could be 
addressed easily by close monitoring of the patient. 
A major issue with MBZ treatment is its poor absorption. MBZ’s limited 
solubility in water and organic solvents exacerbate this problem as it is commonly 
delivered orally. At low does in healthy human volunteers, MBZ absorption ranges from 
5-22%. As dosage increases, the rate of absorption lowers to 1-2% (129). While systemic 
absorption is low, serum levels of MBZ peak one to three hours after intake, at reported 
levels that range from 0.3- 1.7 µM (127, 130). Studies have shown improved 
bioavailability by up to 5-8 fold when taken with a meal rich in fatty foods (131). 
1.6.3.  Anti-Cancer Effects 
1.6.3.1. Preclinical Data 
The Riggins Laboratory at Johns Hopkins first discovered that experimental brain 
tumors were sensitive to benzimidazoles when their mice were no longer receptive to 
xenograft engraftment after veterinary fenbendazole treatment, which was initiated in 
response to a pinworm infestation of their mouse colony. Follow up studies confirmed 
that fenbendazole, and also several other benzimidazoles exhibited the ability to inhibit 
cancer growth in vitro.  ABZ and MBZ showed the greatest potency (132). The efficacy 
of ABZ and MBZ was evaluated against several models of glioblastoma multiforme 
(GBM) in vivo, including mouse GL261 and human 060919. Of all the benzimidazoles 
tested, MBZ consistently showed the greatest therapeutic response. MBZ is able to 
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successfully cross the blood brain barrier and significantly extend survival both as a 
monotherapy and in combination with temozolomide, a standard therapy for GBM.  
MBZ antitumor effects were first published in 2002, regarding its efficacy against 
several lung cancer models both in vitro and in vivo (133). The MBZ treatment of non 
small cell lung cancer cells caused mitotic arrest followed by apoptotic cell death, with 
caspase activation and cytochrome c release (134). It was also noted that MBZ induced 
abnormal spindle formation. MBZ was shown effective against adrenocortical carcinoma 
both in vitro and in vivo, while also successfully blocking an invasion assay of H295R 
cells (135). 
In 2008, the Orlow group screened 2,000 compounds in search of a novel therapy 
that would show efficacy against melanoma, but would be nontoxic to melanocytes. Only 
ten compounds out of the entire library satisfied these criteria. Of the ten hits, 
surprisingly four were of the same benzimidazole class (MBZ, ABZ, FBZ, and 
oxybendazole) (136). Mebendazole exhibited the greatest degree of potency among the 
benzimidazoles. In multiple chemoresistant melanoma cell lines, MBZ reduced 
proliferation, and induced caspase cascade activation, and disrupted microtubule 
polymerization as seen in previous cancers. A follow up study confirmed the ability of 
MBZ to inhibit growth of melanomas in vivo as effectively as temozolomide (137). Both 
studies proposed that the growth suppression seen by MBZ treatment functions in part by 
inhibition B-cell lymphoma 2 (BCL-2) by phosphorylation and proteasomal degradation 
of X-linked inhibitor of apoptosis (XIAP). 
 MBZ was also identified by a second screen for compounds with efficacy against 
colon cancer in 2013. 68 compounds exhibited cytotoxicity including members of the 
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benzimidazole class: MBZ, ABZ, FBZ, and oxybendazole (138). ABZ and MBZ had 
their efficacy analyzed against the NCI 60 cell line panel and surprisingly showed only 
modest correlation between the two compounds (Pearson’s correlation coefficient of 
0.64). The investigators explored the difference in efficacy between the two FDA 
approved benzimidazoles by testing their binding affinities at 10 µM in a high throughput 
binding assay. MBZ had interactions with several protein kinases which ABZ did not, 
including BCR-ABL, BRAF, PDGFRA, MEK1, KIT, JNK1, and more. An unrelated 
study used a novel rapid computational proteochemometric method that predicted and 
confirmed that MBZ was able to bind directly to VEGFR2 kinase and inhibit 
angiogenesis in human umbilical vein endothelial cells (HUVEC) cells (139). When 
testing the inhibitory effect of MBZ in various colon cancer lines this group found that 
MBZ shows greater growth suppression against cancer lines over immortalized 
fibroblasts (138). 
The anticancer effect of MBZ defies a simple explanation. MBZ and related 
compounds have been reported to cause growth arrest and induce apoptosis in cultured 
cancer cells at doses that have little effect on non-cancer immortalized cells (133, 134, 
136, 138, 140). The initial MBZ paper also noted this differential effect as both lung 
cancer lines A549 and H460 were substantially inhibited at 10 µM of MBZ, but the same 
dose had no effect on the proliferation of either HUVEC or WI-38 (lung fibroblasts) 
(133).  
Since the initial report documenting the efficacy of MBZ in human cancer, there 
have been several proposed mechanisms. Most studies assumed the anticancer effect of 
MBZ was a consequence of microtubule inhibition that can lead to impaired structural 
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cellular integrity that affects cell division, cellular transport and migration (123). It is 
unclear why nonspecific antiproliferative effects of tubulin inhibition would 
preferentially target tumor cells over the cells in normal renewing tissues. Alternative 
mechanisms of MBZ have also been proposed including VEGF and HIF-1α inhibition 
and BCL-2 inactivation (135, 139). In lung cancers, MBZ was able to arrest cells at the 
G2-M phase before the onset of apoptosis from cytochrome c release (133). In addition, a 
reduction of angiogenesis was seen in MBZ treated lung tumors. The possibility of MBZ 
inhibiting of critical enzymes through its unique structure has been proposed as well 
(138, 139).  
1.6.3.2. Case Reports  
Patient case studies provide some of the most convincing data regarding the 
anticancer effects of MBZ. The first case report on MBZ in cancer was published in 
2010. In this case, a patient with metastatic adrenocortical carcinoma was treated with 
MBZ as a monotherapy (141). After surgical resection of the tumor, systemic 
chemotherapeutic treatments of 5-fluorouracil, streptozotocin, bevacizumab, and 
mitotane did not stop disease progression. MBZ was considered as a potential therapy for 
the patient based on its successful inhibition of adrenocortical carcinoma growth in both 
in vitro and in vivo models. All other chemotherapeutic therapies were ceased and the 
patient began MBZ monotherapy at standard anthelmintic dosing of 100 mg, twice daily. 
For pain control, the patient also received palliative radiation to the right adrenal 
metastasis. After two months of MBZ monotherapy the diameter of the hepatic 
metastases had decreased 17-42%. The metastases remained stable for 19 months of 
monotherapy without any adverse effects. The patient quality of life returned back to 
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baseline during treatment without symptoms of nausea or weight loss and had no 
abnormalities in his metabolic panel with a complete blood cell count. As is characteristic 
with most chemotherapeutic agents in adrenocortical carcinoma, response is generally 
short lived and subsequent disease progression occurred in the patient following 24 
months of continuous MBZ monotherapy. The case documents the first successful 
application of long-term MBZ treatment against cancer progression without any adverse 
side effects. 
A second case report of MBZ as a monotherapy against metastatic colon cancer 
was published as a follow up to the preclinical findings in 2013 (142). A 74 year old male 
presented with an advanced sigmoid colon cancer and multiple bilateral lung and 
paraaortic lymph node metastases. First line therapy involved palliative chemotherapy 
with capecitabine, oxaliplatin, and bevacizumab. However, due to neuropathy induced by 
oxaliplatin, an alternative second line therapy with irinotecan was instated. Disease 
progression was observed in lungs and abdominal lymph nodes and presentation of new 
metastases on the liver. Without any standard therapeutic options remaining, the patient 
consented to MBZ monotherapy based on previous preclinical data supporting efficacy 
against colon cancer. The patient followed the same dosage pattern of the first case report 
of oral delivery of 100 mg twice a day. Treatment continued for six weeks with no 
adverse effects. CT evaluation showed significant liver metastases regression and near 
complete remission of lung and lymph node metastases. Elevated liver enzymes AST and 
ALT caused a temporary stop in MBZ then resumed treatment at half dose. Liver 
enzymes returned to normal and follow up CT scans confirmed stable remission with no 
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adverse side effects reported by the patient. Until CT scans indicate disease progression 
the patient is on strategic treatment interruption.  
1.7. Specific aims and hypothesis of the dissertation 
A diverse range of cancers that are characterized by activated Hh signaling are 
pre-clinically responsive to MBZ and structurally related benzimidazoles.  Recently, Hh 
signaling has been shown to be active in many gliomas (143, 144), while Hh ligands or 
markers of downstream pathway activity have been detected in melanomas, lung cancers, 
ovarian cancers, adrenocortical cancers and colorectal cancers (5, 6, 77-80) , which are 
all responsive to MBZ (133-136, 138, 141, 145). Notably, unbiased screens for novel Hh 
inhibitors have previously identified drugs that interact with microtubules, including 
vinblastine, vincristine, and paclitaxel (106). These drugs potently inhibit mitosis and are 
therefore highly toxic. The specific effects of these compounds on components of the Hh 
pathway have not been reported.   
The potential role of the human PTCH1 homologs in the canonical and 
noncanonical Hh pathways is unclear. I have two related hypotheses. First, I hypothesize 
that MBZ exerts its anticancer effects in whole or in part via inhibition of canonical Hh 
signaling. Second, I hypothesize that PTCH53 controls canonical and noncanonical Hh 
pathways and thereby contributes to p53-dependent inhibition of tumorigenesis.  
Aim 1: Evaluate MBZ’s ability to inhibit Hh signaling in vitro. Evaluate the ability of 
benzimidazoles as a class to effect Hh signaling. Test if MBZ is capable of inhibiting Hh-
dependent cell proliferation and survival. Check for selective growth inhibition based on 
a cell’s Hh dependency.  
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Aim 2: Evaluate MBZ’s ability to inhibit Hh signaling in vivo.. Test if MBZ can 
inhibit the growth of experimental brain tumors in mice. 
Aim 3: Determine the molecular target of MBZ anticancer activity. Restore different 
Hh components to determine the point of Hh interference by MBZ. Evaluate MBZ’s 
effect on SMO translocation, ciliogenesis, and tubulin polymerization.  
Aim 4: Compare MBZ to vismodegib Test MBZ’s effect against vismodegib resistant 
models and the effect of combination of both compounds on Hh signaling. 
Aim 5: Explore the effect of PTCH53 expression on canonical Hh signaling and on 
induction of interferon response genes. Test the effect of PTCH53 on the activation of 





Chapter 2: Materials and Methods 
 
2.1. Cell lines and cell cultures 
Cultures of 293T and hTERT-RPE1 cells and Smo-/- mouse embryo fibroblasts 
(MEFs) were maintained in DMEM (Life Technologies) supplemented with 10% fetal 
bovine serum (FBS; Hyclone) and penicillin/streptomycin.  DAOY and C3H10T1/2 
mouse fibroblast cells were grown in Eagle’s MEM (Life Technologies) supplemented 
with 10% FBS and penicillin/streptomycin. NIH3T3 cells were grown in DMEM 
supplemented with 10% calf serum. Shh Light II cells (93) were grown in DMEM with 
10% calf serum and 0.4mg/ml geneticin and 0.15 mg/ml zeocin, both purchased from 
Life Technologies. HCT116 and RKO colorectal cancer cells and their isogenic 
derivatives (146) were cultured in McCoys 5A supplemented with 10% FBS.  All cell 
lines were obtained from ATCC and validated by the supplier, except for Smo-/- mouse 
embryo fibroblasts which were a gift from James Kim. 
2.2. Orthotopic tumors 
Syngeneic GL261 glioma tumors were grown intracranially in 4-6 week old 
female nu/nu athymic mice (NCI-Fredrick) and treated with MBZ as previously 
described (132). Each brain was snap frozen after extraction and stored in liquid nitrogen 
until further analysis.  Orthotopic medulloblastoma xenografts were generated in female 
athymic mice, 5-6 weeks of age (NCI). DAOY cells expressing luciferase were used for 
brain tumor implantation. For the implantation procedure, mice were first anesthetized. 
With a stereotactic frame, 100,000 DAOY cells were injected through a burr hole drilled 
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1 mm lateral to the right of the sagittal suture and 1 mm posterior to the lambda, at a 
depth of 2.5 mm below the dura at a rate of 1 µl/minute.  Treatment was initiated at 5 
days post implantation, when treated mice received a 25 mg/kg daily dose of MBZ, 
delivered with 50% (v/v) sesame oil and PBS, by gavage. Mice were euthanized when 
they showed signs of increased intracranial pressure. All animal protocols and procedures 
were performed under an approved protocol and in accordance with the Johns Hopkins 
Animal Care and Use Committee guidelines. For RNA preparation, each brain was 
thawed on ice before removing the right anterior cerebral cortex and the contralateral 
brain section. Each tissue sample was suspended in 1 mL of TRIzol (Life Technologies) 
per 0.1 g of material, and the RNA fraction was purified according to the manufacturer’s 
recommendations.  
2.3. Plasmids and cell transfections 
ShhN-conditioned media was generated by transfection of pcDNA3 ShhN 
(provided by Pao Tien Chuang) into 293T cells. Control media was obtained from mock-
transfected 293T cells.  For localization of SMO, hTERT RPE-1 cells grown in chamber 
slides (Nunc) were transfected with pcDNA3 Smo-FLAG (provided by Chen Ming Fan).  
GLI1 reporter assays were conducted by cotransfecting the firefly luciferase reporter 
pBV Luc 8xGli (provided by Craig Peacock) and TK-renilla luciferase reporter pGL4 74 
(Promega). Overexpression of Hh components was achieved by transient transfection of 
pRK-SmoM2 (147), pCMV5 hGLI1 FLAG (provided by Peter Zaphiropoulos), and 
pCS2-MT hGLI2 FL (Addgene plasmid 17648) (148). Mutant-Smo expression constructs 
were provided by James Kim. PTCH53 Hh suppression was analyzed by transient 
transfection of pCDNA3.1-PTCH53 (provided by Jon Chung), pCDNA3.1-PTCHD1-
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Myc (provided by John Vincent) (149), pCI-PTCH1-FLAG (provided by Takashi 
Shimokawa) (150). All transfections were performed with FuGENE HD (Promega). 
2.4. GLI-reporter assays and drug treatment 
Subconfluent Shh Light II cells were routinely incubated in low serum conditions 
(0.25% fetal bovine serum, 5 mm HEPES), to optimize Hh responsiveness, during a 48 h 
period of drug treatment. For ShhN ligand stimulation, cells were incubated with ShhN-
conditioned media or control media, diluted 1:5, during the treatment period. Final 
DMSO concentration in all cultures was 1%. For experiments involving overexpression 
of Hh pathway components, cells were transfected 24 h prior to low serum and drug 
treatment.  Cell lysates were analyzed using the Dual Luciferase Assay Reporter System 
(Promega). GLI-dependent luciferase was measured on a Victor3 V 1420 Multilabel 
Counter (Perkin Elmer) and standardized against renilla luciferase activity.  The IC50 was 
calculated by Prism 5 software package (GraphPad). 
For the assessment of Gli-luc activity relative to PTCH53 overexpression, Smo-/- 
mouse embryo fibroblasts were transfected with 200 ng Gli-luciferase reporter plasmid, 
200 ng pGL4.74,150 ng SMO plasmid and varying mass ratios of PTCH1, PTCHD1, 
PTCH53 expression plasmids.  Each well was split into three wells of a 24 well plate 8h 
after transfection, After 24 h, media was replaced with DMEM containing reduced serum 
(0.5% FBS). Lysates were collected for analysis 72 h after transfection. All experiments 
were performed in triplicate with at least 3 independent experiments. 
2.5. Cell proliferation, viability and survival assays 
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BrdU incorporation during DNA synthesis was measured using the Cell 
Proliferation ELISA kit (Roche). Cell viability was measured with the Cell Titer-Blue 
Cell Viability Assay kit (Promega). Colorimetric signals were measured on a SpectraMax 
M5 (Molecular Devices).   For each assay, the IC50 was calculated with the Prism 5 
software package (GraphPad). For assessment of clonogenic survival, cells were drug-
treated under low serum conditions in 12 well plates. After 48 h, cells were harvested in 
trypsin-EDTA (Life Technologies), diluted 1:4000 in standard growth media and seeded 
in 10 cm plates, in triplicate. After 10 days of growth, plates were stained with 0.2% 
crystal violet in 50% MeOH and destained in water. Colonies containing more than 50 
cells were scored.  
2.6. Immunoblots and immunofluorescence 
Proteins were separated on Bis-Tris gels (Life Technologies) and transferred onto 
Immobilion-P nylon membranes (Millipore). Following overnight incubation with 
primary antibodies under standard conditions, blots were developed with HRP-
conjugated secondary antibodies and visualized by chemiluminescence (Amersham). 
Band intensities were quantified by Image Lab software and standardized to the intensity 
of the loading controls anti-α-tubulin or anti-β-actin. To assess tubulin polymerization, 
polymerized and unpolymerized tubulin fractions were separated on the basis of 
solubility as reported previously (151). 
For analysis of primary cilia by immunofluorescence, cells were grown on poly-
D-lysine (Sigma) coated chamber slides (Nunc) and fixed in 0.4% paraformaldehye at 
37°C for 5 min, permeabilized in 0.5% Triton X-100 at 37°C for 2 min, washed in PBS, 
then sequentially incubated in 4% paraformaldehyde, 37°C for 5 min, and methanol, -
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20°C for 5 min, as previously described (152). Nonspecific proteins were blocked with 
2% bovine serum albumin in PBS for 30 min at RT. Slides were incubated with primary 
antibody in blocking buffer overnight at 4°C, then washed with PBS and incubated with 
either biotinylated (Santa Cruz Biotechnology) o/r Alexa Fluor 594-conjugated (Life 
Technologies) secondary antibodies in blocking buffer for  20 min at room temperature. 
Cells were washed with PBS before adding an Alexa Fluor 488-streptavidin conjugate 
(Life Technologies). Nuclei were counterstained with 4',6-diamidino-2-
phenylindole (DAPI; Life Technologies). Stained cells were visualized with an 
AxioImager Z1 (Carl Zeiss) and images were captured with Axiovision Rel 4.6 software.  
The following primary antibodies were used: anti-GLI1 (C68H3; Cell Signaling), 
anti-cleaved caspase 3 (D175; Cell Signaling), anti-α-tubulin (TU-02; Santa Cruz), HRP-
conjugated anti-β-actin (Santa Cruz), anti-acetylated α-tubulin (6-11 B-1; Sigma), anti-
FLAG (anti-DYKDDDDK; Cell Signaling), anti-MX2 (N-17; Santa Cruz).  
2.7. Quantitative real time RT-PCR 
RNA was isolated and purified with the TRIzol reagent (Life Technologies), 
treated with DNase I (Thermo Scientific)  and assayed by spectrophotometry. cDNA was 
synthesized with the Maxima First Strand cDNA synthesis kit (Thermo Scientific). 
Quantitative, real time reverse-transcription PCR (qRT-PCR) was performed using both 
Maxima Probe and Maxima SYBR Green qPCR Master Mixes (Thermo Scientific) with 
standard cycling conditions on a 7900HT Fast Real-Time PCR system (Applied 
Biosystems). Prime Time qPCR probes and primers were used to assay the mouse genes: 
Ptch1: probe (5’-ATTCGGACCCTGCAAGCATCAGT-3’), forward primer (5’-
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TGTTTGCTCCCGTTCTGG-3’), reverse primer (5’-AACCAGTCCATTGAGAACCC-
3’);  Gli1: probe (5’-CTGGGACCCTGACATAAAGTTGGCT-3’); forward primer (5’-
CTTTCTGGTCTGCCCTTTTG-3’); reverse primer (5’-
TCTTTGTTAATTTGACTGAACTCCG-3’);  Rpl19: probe (5’-
CTTCTCAGGAGATACCGGGAATCCAAG-3’); forward primer (5’-
AGAAGGTGACCTGGATGAGAA-3’); reverse primer (5’-
TGATACATATGGCGGTCAATCT-3’). Human transcripts were analyzed with SYBR 
green. GLI1: forward primer (5’-CCACGGGGAGCGGAAGGAG-3’); reverse primer 
(5’-ACTGGCATTGCTGAAGGCTTTACTG-3’). PTCH1: forward primer (5’-
CCACAGAAGCGCTCCTACA-3’); reverse primer (5’-CTGTAATTTCGCCCCTTCC-
3’). GAPDH: forward primer (5’-CGGAGTCAACGGATTTGGTCGTAT-3’); reverse 
primer (5’-AGCCTTCTCCATGGTGGTGAAGAC-3’). PTCH53: forward primer (5’-
AAGCCAGCTCTATTCGGACTTAC-3’); reverse primer (5’-
ACTTGACCCGCTGATCTTTG-3’). CDKN1A: forward primer (5’-
ACAGCAGAGGAAGACCATGTG-3’); reverse primer (5’-
GGGCTTCCTCTTGGAGAAGAT-3’). PTCH1: forward primer (5’-
CCACAGAAGCGCTCCTACA-3’); reverse primer (5’-CTGTAATTTCGCCCCTTCC-
3’). BST2: forward primer (5’-CACACTGTGATGGCCCTAATG-3’); reverse primer 
(5’-GTCCGCGATTCTCACGCTT-3’). IFI27: forward primer (5’-
TGCTCTCACCTCATCAGCAGT-3’); reverse primer (5’-
CACAACTCCTCCAATCACAACT-3’). IFI44L: forward primer (5’-
AGCCGTCAGGGATGTACTATAAC-3’); reverse primer (5’-
AGGGAATCATTTGGCTCTGTAGA-3’). IFI6: forward primer (5’-
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GTCTGCGATCCTGAATGGG-3’); reverse primer (5’-
TCACTATCGAGATACTTGTGGGT-3’). IFIH1: forward primer (5’-
TCGAATGGGTATTCCACAGACG-3’); reverse primer (5’-
GTGGCGACTGTCCTCTGAA-3’). IFIT1: forward primer (5’-
TTGATGACGATGAAATGCCTGA-3’); reverse primer (5’-
CAGGTCACCAGACTCCTCAC-3’). IFITM1: forward primer (5’-
TGATCAACATCCACAGCGAGAC-3’); reverse primer (5’-
TCCTGTCCCTAGACTTCACGGA-3’). ISG15: forward primer (5’-
CGCAGATCACCCAGAAGATCG-3’); reverse primer (5’-
TTCGTCGCATTTGTCCACCA-3’). MX2: forward primer (5’-
CAGAGGCAGCGGAATCGTAA-3’); reverse primer (5’-
TGAAGCTCTAGCTCGGTGTTC-3’). OAS1: forward primer (5’-
TGTCCAAGGTGGTAAAGGGTG-3’); reverse primer (5’-
CCGGCGATTTAACTGATCCTG-3’). OAS2: forward primer (5’-
CTCAGAAGCTGGGTTGGTTTAT-3’); reverse primer (5’-
ACCATCTCGTCGATCAGTGTC-3’). OAS3: forward primer (5’-
GAAGGAGTTCGTAGAGAAGGCG-3’); reverse primer (5’-
CCCTTGACAGTTTTCAGCACC-3’). OASL: forward primer (5’-
CTGATGCAGGAACTGTATAGCAC-3’); reverse primer (5’-
CACAGCGTCTAGCACCTCTT-3’). SAMHD1: forward primer (5’-
CTGGAACTCCATCCCGACTAC-3’); reverse primer (5’-
AGTAATGCGCCTGTGATTTCAT-3’). USP18: forward primer (5’-
CCTGAGGCAAATCTGTCAGTC-3’); reverse primer (5’-
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CGAACACCTGAATCAAGGAGTTA-3’). All results were analyzed using SDS RQ 
Manager (Applied Biosystems).  
2.8. Interferon and interferon stimulating DNA 
All cells treated with human IFN-α1 (Cell Signaling) were treated at 100ng/mL in 
low serum conditions. Cells were transiently transfected with interferon stimulating DNA 
(ISD) and ISD Control (InvivoGen) at 1 µg/mL with FugeneHD for 24 h before changing 
to low serum for 48 h. 
2.9. Statistics 
Two-tailed t-tests were used to assess significance.  *, p<0.05  **, p<0.02  ***, 
p<0.005.  Error bars indicate standard error of the mean unless otherwise indicated. For 
survival curve comparison, the Prism 5 software package (GraphPad) was used to 




Chapter 3: Results 
 
3.1. Mebendazole inhibits Hh signaling 
To directly assess the effect of MBZ on canonical Hh signaling, we incubated the 
drug with murine Shh-Light II cells, which have stably incorporated a GLI-activated 
firefly luciferase (Gli-luc) reporter construct (93). Under low serum conditions that are 
optimal for Hh activation, addition of the amino-terminal signaling domain of the 
secreted Sonic Hedgehog ligand (ShhN) induced robust reporter activity that could be 
inhibited by MBZ in the micromolar dose range (Fig. 3.1.A). A similar degree of 
inhibition was observed in mouse C3H10T1/2 fibroblast cells transiently transfected with 
the Gli-luc reporter (Fig. 3.1.B). MBZ was a considerably more potent inhibitor of Hh 
pathway activation than structurally related antihelminthic drugs (Fig. 3.2), which in 
prior studies were less effective than MBZ at inhibiting the growth of GL261 gliomas 
(132). The GL261 mouse tumor harbors a mutation in Pten (153); in humans, mutation of 
PTEN defines a category of gliomas that are strongly associated with elevated Hh activity 
(144).  We assessed endogenous Gli1 transcript levels in MBZ-treated and control GL261 
tumors. Gli1 expression was significantly elevated in untreated tumors compared with 
non-affected tissue from the contralateral side of the brain (Fig. 3.3.A), suggesting a role 
for Hh signaling in the growth of these tumors. Gli1 expression in tumor tissues was 
decreased by MBZ treatment (Fig. 3.3.B). To extend our analysis to human cells, we 
tested the effects of MBZ on Hh-mediated gene expression in the immortalized human 
retinal pigment epithelial cell line hTERT-RPE1. Unlike the majority of human cancer 
cell lines, this non-cancer cell line is responsive to ShhN (Fig. 3.4). A concentration of 
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0.1 µM MBZ was sufficient to reduce ShhN-induced expression of endogenous GLI1 and 
PTCH1 to basal levels (Fig. 3.4). Further Hh pathway inhibition was observed at higher 







Figure 3.1. MBZ inhibits Gli1 in luciferase reporter system 
(A) Shh-Light II cells maintained in low serum conditions were incubated in ShhN-
conditioned medium or control medium, in the presence of MBZ at the indicated 
concentrations.  The activity of the stably integrated Gli-luc reporter was measured after 
48 h of treatment. (B) C3H10T1/2 mouse fibroblasts were co-transfected with the Gli-luc 
and renilla luciferase reporters. After 24 h, MBZ was added for an additional 48 h in low 







Figure 3.2. Hh inhibition by benzimidazoles 
The effect of MBZ on Gli-luc reporter activity in Shh-Light2 cells was compared with 
that of the structurally related benzamidizoles albendazole, fenbendazole, and 






Figure 3.3. MBZ inhibits Hh signaling in GL261 in vivo  
(A) Endogenous levels of Gli1 transcripts in syngeneic, GL261 gliomas and in normal 
brain tissue from the contralateral region were measured by qRT-PCR. (B) Gli1 
expression was measured by qRT-PCR in untreated and MBZ-treated GL261 tumors. 
Each measurement was standardized to a parallel measurement from a contralateral brain 





Figure 3.4. MBZ suppresses GLI1 and PTCH1 in hTERT-RPE1 cells in vitro 
hTERT-RPE1 cells growing in low serum were treated with ShhN-conditioned or control 
medium for 48 h. MBZ was included during this treatment period at the concentrations 






3.2. Effect of mebendazole on Hh signaling, growth and survival of Hh 
dependent medulloblastoma cells 
The effects of MBZ on Hh-dependent cell proliferation and survival were next 
assessed in the human medulloblastoma cell line DAOY. DAOY cells have a gene 
expression profile consistent with a type 2 (Hh-subtype) medulloblastoma and 
accordingly exhibit elevated Hh signaling (154). MBZ caused a reduction in GLI1 
expression, IC50=516 ±81 nM (SEM); (Fig. 3.5.B) and could also inhibit the increased 
expression of GLI1 and PTCH1 observed after addition of ShhN ligand (Fig. 3.5.A). At 
similar concentrations MBZ markedly inhibited DAOY cell proliferation (Fig. 3.6.A) and 
reduced clonogenic survival (Fig. 3.6.B).  The viability of DAOY cells was significantly 
impaired by MBZ at concentrations approaching 1 µM.  In contrast, hTERT RPE-1 cells, 
which are Hh-responsive but not dependent on Hh signals for growth, were only 
modestly affected (Fig. 3.7.A). The expression of GLI1 protein was similarly reduced in 
both cell types by increasing concentrations of MBZ, but only DAOY cells exhibited 
biochemical ((Fig. 3.7.B) and morphological (Fig. 3.8) evidence of apoptosis.  When 
injected into the cerebella of nude mice to form orthotopic xenografts, DAOY cells were 
responsive to MBZ administered by daily gavage. MBZ treatment suppressed levels of 
GLI1 transcripts in the DAOY-derived tumors (Fig. 3.9.A) and significantly extended 
survival (p=0.01; Fig. 3.9.B). Notably, DAOY xenografts exhibit large cell morphology 




Figure 3.5. MBZ suppresses GLI1 and PTCH1 in DAOY cells in vitro  
(A) Subconfluent DAOY cells were incubated under low serum conditions with ShhN-
conditioned or control medium for 48 hrs and treated during this period with MBZ at 
varying concentrations. Transcript levels were assessed by qRT-PCR. (B) DAOY cells 
were grown for 48 hours in low serum conditions with a range of MBZ concentrations 






Figure 3.6. MBZ reduces proliferation and clonogenicity in DAOY cells 
Subconfluent DAOY cells were incubated under low serum conditions for 48 hrs and 
treated during this period with MBZ at varying concentrations. (A)  Cell proliferation was 
assessed by measuring the incorporation of BrdU over 2 h, following drug treatment. (B) 





Figure 3.7. MBZ effect on cell viability of DAOY and hTERT-RPE1 cells 
Subconfluent DAOY cells were incubated under low serum conditions for 48 hrs and 
treated during this period with MBZ at varying concentrations. (A) The effect of MBZ on 
cell viability was comparatively assessed by CellTiter-Blue in hTERT-RPE1 (blue) and 
DAOY (red). (B) The expression of GLI1 protein and cleavage of caspase-3 were 
assessed by immunoblot in DAOY and hTERT-RPE1 cells treated with MBZ for 12 h, 





Figure 3.8. Apoptosis in DAOY cells 
DAOY cells incubated under the same conditions as Fig 3.6. Representative nuclei from 







Figure 3.9. MBZ extends survival and inhibits GLI1 expression in DAOY cells 
grown as xenograft tumors in vivo 
(A) DAOY cells were grown as orthotopic xenografts following injection into the 
cerebella of nude mice. After 5 d, mice were treated with 25 mg/kg MBZ (n=4) or mock-
treated (n=3). One mouse from the mock treatment group did not develop symptoms of a 
growing brain tumor, and was euthanized after surviving for more than six months.  This 
mouse was not found to have a brain tumor, and was therefore omitted from this analysis. 
Total RNA was harvested from representative tumors at the time of death and GLI1 







3.3. Mebendazole inhibits activation of SMO 
We next tested the ability of MBZ to counteract Hh signaling induced by 
individual components of the pathway. NIH3T3 cells strongly activated the Gli-luc 
reporter in response to ShhN-conditioned medium; this upregulation of Hh activity was 
suppressed by MBZ and by vismodegib (Fig. 3.10.A). Hh signaling could also be 
strongly stimulated in these cells by transient overexpression of the Ptch1-resistant 
SmoM2 mutant protein (147), and by GLI1 or GLI2 (Fig. 3.10.B). The stimulatory effect 
of SmoM2 on Gli-luc activation could be suppressed by MBZ, whereas reporter 





Figure 3.10. Relative Gli1 stimulation in 3T3 cells 
(A) NIH3T3 fibroblasts co-transfected with Gli-luc and renilla reporter plasmids were 
maintained in low serum conditions for 48 h in the presence of ShhN-conditioned or 
control media.  During this period, MBZ or vismodegib were added at the indicated 
concentrations. (B) A direct comparison of Gli-luc activation in NIH3T3 cells 48 h after 
treatment with ShhN ligand, or 72 h after cotransfection with plasmids that drive 






Figure 3.11. Gli1 signaling rescued from MBZ by restoration of Hh components 
MBZ or vismodegib was added to SmoM2-, GLI1-, or GLI2-transfected NIH3T3 cells 
during 48 h of incubation in low serum conditions. The activation of a co-transfected Gli-
luc reporter by each overexpressed gene, in the absence of drug treatment, was 




3.4. Mebendazole inhibits formation of primary cilia 
To assess the effect of MBZ on upstream signaling by SMO, we examined the 
cellular localization of a Smo-FLAG fusion protein (156) by immunofluorescence. Under 
low serum conditions that favor primary cilium formation and robust SMO activation, 
Smo-FLAG was predominantly localized to the primary cilia (Fig. 3.12). MBZ-treated 
cells exhibited a notable paucity of primary cilia. In non-ciliated cells Smo-FLAG was 
distributed throughout the cytoplasm (Fig. 3.12). The suppressive effect of MBZ on 
ciliogenesis was quantified in larger cell populations (Fig. 3.13.A and Fig. 3.13.B). The 
proportion of ciliated cells decreased in response to MBZ within a concentration range 
that also inhibited the polymerization of human β-tubulin in vitro (Fig. 3.14.A and 
3.14.B).  We next tested whether allowing primary cilia to pre-form prior to MBZ 
addition could alter the effect of MBZ on pathway activity.  Temporally separating serum 
starvation from MBZ administration partially restored GLI1 expression (Fig. 3.15.A) and 




Figure 3.12. Visualizing Smo localization relative to primary cilia 
A Smo-FLAG fusion protein was expressed in hTERT-RPE1 cells following transient 
transfection. After 48 h incubation in low serum and treatment with 1 uM MBZ or 
vehicle, cells were fixed, permeabilized and stained with antibodies directed against 
acetyl-α-tubulin (green) and FLAG (red).  Nuclei were counterstained with DAPI. Scale 





Figure 3.13. MBZ quantitatively inhibits ciliogenesis 
(A) Cilia were numerically assessed by acetyl-α-tubulin staining in hTERT-RPE1 cells 
maintained in low serum conditions and treated with MBZ. Primary cilia (indicated by 
arrows) could be visualized on individual cells (inset). Scale bar, 20 µm. (B) The effects 
of MBZ or 0.2 µM vismodegib (red line) on the proportions of ciliated cells, expressed as 




Figure 3.14 MBZ inhibits tubulin polymerization 
hTERT-RPE1 cells were treated with MBZ at the indicated concentrations or with 10 nM 
paclitaxel (red line) for 48 h under low serum conditions. Polymerized and 
unpolymerized tubulin fractions were quantified by immunobloting, (A) normalized to 
the loading control β-actin, and expressed as the proportion of polymerized tubulin 







Figure 3.15. Serum starvation reduces MBZ effect on GLI1 and proliferation  
(A) GLI1 expression was assessed in DAOY cells that were incubated with MBZ for 48 h 
under the low serum conditions that allow formation of the primary cilium (“Treat in low 
serum”), or that were first maintained in low serum for 20 h prior to before adding MBZ 
for an additional 48 h (“Pre-incubate in low serum”). (B) Cell viability was assessed by 




3.5. Additive effect of mebendazole and vismodegib against SMO-
dependent, canonical Hh signaling 
3.5.1. MBZ inhibits vismodegib resistance Smo 
As MBZ exerts an indirect effect on SMO, we reasoned that MBZ might inhibit 
the activity of mutant SMO proteins that have been found to confer vismodegib 
resistance. To test this idea, we assayed the ability of MBZ to inhibit Gli-luc activation 
by wild type and vismodegib-resistant mutant Smo proteins exogenously expressed in 
Smo
-/- 
mouse embryo fibroblasts. Gli-luc activity was induced by Shh ligand in the 
presence of either wild type Smo or the Smo D477G mutant. This mutation was originally 
found in a vismodegib-resistant allograft derived from a mouse medulloblastoma and 
corresponds to an equivalent mutation found in a patient with recurrent disease (103). 
Activation of Gli-luc by Smo D477G was completely resistant to inhibition by 
vismodegib (Fig. 3.16.A).  In contrast, both wild type and mutant Smo could be 
functionally suppressed by MBZ (Fig. 3.16.B).  Analysis of an expanded panel of all 
described vismodegib-resistant Smo mutants (104) confirmed that the inhibitory effects of 
MBZ were unaffected by the vismodegib-selected alterations in Smo (Fig. 3.17). 
3.5.2. Additive effect 
When used in combination (Fig. 3.18.A and Fig. 3.18.B), vismodegib and MBZ 
additively suppressed the Gli-luc signal (Fig. 3.19), a result that is consistent with two 





Figure 3.16. MBZ inhibits the vismodegib resistant Smo D477G mutant  
Wild type Smo or the Smo D477G mutant were expressed with the Gli-luc and renilla 
luciferase reporters by co-transfection into Smo-/- MEFs. After 24 h, cells were treated 
with (A) vismodegib or (B) MBZ at the indicated concentrations, in the presence of 





Figure 3.17. MBZ inhibits a panel of vismodegib resistant SMO mutant proteins  
The effects of 1 µM MBZ and 0.2 µM vismodegib on Smo-dependent activation of the 
Gli-luc reporter were assessed against an expanded panel of Smo mutants in Smo-/- 





Figure 3.18. MBZ and vismodegib exert combinatorial effect on Hh 
(A) The combined effects of vismodegib and MBZ on relative Gli-luc activity were 
tested in Shh Light2 cells under low serum conditions with supplemental ShhN-media 
(B) A modification of the experiment shown in A, in which MBZ was titrated into the 








Figure 3.19 MBZ has an additive effect with vismodegib 
The relative luciferase readout of Fig 3.19.A was normalized to 100 for each MBZ 
concentration, so that the curves could be superimposed. The IC50 of vismodegib was 




3.6. Inhibition of canonical Hh signaling by PTCH53 
The canonical hedgehog pathway is negatively regulated by PTCH1, which 
suppresses SMO activity, and thereby blocks the downstream activation of the GLI 
family of transcription factors. Other PTCH1 homologs, such as PTCHD1, also suppress 
SMO and thereby inhibit downstream Hh activation, but at reduced efficacy compared 
with PTCH1.  
Considering the homology shared by PTCH53 and PTCH1, we decided to test 
whether PTCH53 could suppress the canonical Hh pathway. The experiment employed 
the same cell line and luciferase reporter system used in Fig 3.16 and 3.17. Smo -/- mouse 
embryonic fibroblasts were transfected with a downstream luciferase reporter with eight 
Gli binding sites. The ability of each PTCH1 homolog (PTCH53, PTCH1, and PTCHD1) 
to suppress Gli activation was compared, by varying the ratio of each Patched protein to 
SMO in the transfection (Fig 3.20).  PTCH53 was able to suppress canonical Gli1 
activation by SMO in a dose dependent manner, to an extent that was comparable to the 
evolutionarily similar PTCHD1. However, PTCH53 showed a reduced ability of Hh 







Figure 3.20. Inhibition of canonical Hh signaling by PTCH53   
Smo-/- mouse embryonic fibroblasts were co-transfected with a SMO expression plasmid, 
a Gli-luciferase reporter and plasmids that direct the expression of PTCH53, PTCH1 or 
PTCHD1, at the indicated SMO:PTCH mass ratios. Luciferase activity was assessed 72 h 
after transfection. Renilla luciferase activity was used to normalize transfection 




3.7 Regulation of interferon-response genes by PTCH53 
A noncanonical function of PTCH53 was suggested by the previous observation 
that its overexpression induced the upregulation of a set of IFN response genes (Fig 1.2.B 
& 1.2.C). I showed that the same gene subset was upregulated in standard hTERT-RPE1 
cells by IFN stimulation (Fig. 2.21). Stimulation by either IFN or PTCH53 
overexpression caused MX2 transcription to be induced more than any other gene, by 1-2 
log folds. MX2 is a critical response element at inhibiting the infection of cells by human 
immunodeficiency virus 1 (HIV-1), vesicular stomatitis virus, and mouse herpes virus 
type 68 (157-160).  
We used a series of p53 isogenic cell lines and cell lines with doxycycline-
inducible PTCH53 shRNA to further investigate the link between PTCH53 and induction 
of MX2. Partial knockdown of PTCH53 by doxycycline-induced shRNA caused a 
decrease in IFN-stimulated MX2 transcripts (Fig 3.22.A) and IFN-induced MX2 protein 
(Fig 3.22.B). MX2 could also be induced by transfection with a 45-bp non-CpG 
oligomeric DNA, derived from the Listeria monocytogenes genome, which is a potent 
stimulus of the type 1 IFN response, but not by a single-stranded, non-stimulatory DNA 
with the same sequence (Fig. 2.22.C). PTCH53 and the p53-target gene CDKN1A were 
modestly induced after transfection with either DNA. Knockdown of PTCH53 expression 
attenuated the response of MX2 to interferon-stimulatory DNA (Fig. 2.22.C).  We next 
employed isogenic colorectal cancer cells differing in functional p53 expression and 
therefore their ability to upregulate PTCH53. MX2 induction by IFN was significantly 
higher in TP53+/+ cells, compared to isogenic TP53-/- cells in both HCT116 (Fig. 23) 





Figure 3.21. IFN induces the same panel of genes as PTCH53 overexpression 
hTERT-RPE1 cells grown in low serum conditions were treated with IFN or vehicle for 
12 h. Transcripts of the 15 PTCH53-responsive interferon signature genes were assessed 
by qRT-PCR. IFN-induced expression of each gene was normalized to the uninduced 






Figure 3.22. Modulation of MX2 expression by PTCH53 knockdown 
 (A) hTERT RPE1 cells with doxycycline-inducible PTCH53 shRNA were grown in low 
serum conditions and treated with or without doxycycline for 24 h prior to treatment with 
IFN or vehicle for 12 h. Transcripts were measured by qRT-PCR. (B) Cells were grown 
and treated under the same conditions as (A)  and protein was harvested at 24 h. (C) 
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hTERT RPE1 cells with doxycycline-inducible PTCH53 shRNA, grown in low serum 





Figure 3.23 p53 dependent IFN induced MX2 response in HCT116 cells 
Isogenic TP53 +/+ and TP53 -/- HCT116 cells were treated with IFN or vehicle for 12 h 




Figure 3.24 p53 dependent IFN induced response in RKO cells 
Isogenic TP53 +/+ and TP53 -/- RKO cells were treated with IFN or vehicle for 12 h in 






Chapter 4: Discussion 
 
4.1. Repurposing the anthelminthic mebendazole as a hedgehog 
inhibitor   
The development of new drugs for the treatment of cancers is a time consuming 
and expensive process. Unanticipated toxicities at all stages of development are a major 
cause of failure (161). Repurposing well characterized compounds for new uses can 
minimize such uncertainty, save time and markedly reduce costs. There are over 4000 
unique molecular entities approved worldwide for human or veterinary use (162). 
Exploring new indications for this rich compound library is a particularly attractive 
strategy to find new treatments for rare and neglected diseases, for which there are few 
financial incentives to justify the traditional process of commercial drug discovery.  Brain 
tumors are relatively rare, but highly lethal. The incidence of medulloblastoma, for 
example, is approximately 1.5 per million in the US and the majority of these cases occur 
in children (163). Economic constraints and the unique vulnerability of pediatric patients 
are obstacles to the traditional drug discovery process.  New strategies to treat such 
diseases will likely involve agents that are first approved for other purposes. 
The low-avidity binding of MBZ to human tubulin does not evidently affect 
essential processes such as mitosis in normal renewing cell populations, but as we show 
here this interaction can inhibit the assembly of the primary cilium, a tubulin-based 
structure. Hh pathway components are concentrated in the primary cilium (4, 164), and 
mutations in murine genes necessary for cilium formation cause phenotypes consistent 
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with deficiencies in Hh signaling (165). In mice, primary cilia are dispensable for the 
growth of fibroblasts and other cell types, but essential for the ongoing proliferation of 
cultured medulloblastoma cells and the growth of established tumors (166). The 
differences in MBZ sensitivity that we observed between human medulloblastoma cells 
and immortalized cells (Fig. 3.7) are consistent with these dependencies.  
The efficiency with which MBZ can inhibit the formation of the primary cilium 
suggests that this anti-Hh effect might account for much of its activity against brain 
tumors and other tumor types thus far tested. Effects on other targets may also be 
relevant. For example, signals arising from WNT and PDGF ligands travel through the 
primary cilium (3). However, the developmental abnormalities that arise in mutant mice 
deficient for ciliogenesis are distinct from what is observed when the WNT or PDGF-
pathways are genetically altered, and most clearly overlap with those caused by Hh 
signaling defects (3). Beyond the primary cilium, microtubule assembly plays a 
fundamental role in cell division. Our results cannot rule out effects of MBZ on the 
mitotic spindle, but this type of antiproliferative activity is not highly specific for cancer 
cells.  Indeed, mitotic spindle checkpoint defects that are found in many cancers have 
been proposed to confer relative resistance to microtubule inhibitors (167).  Interestingly, 
MBZ-treated xenografts have been found to exhibit reduced vascularity (133), and 
VEGF-A has accordingly been proposed as a target of benzimidazole therapy (145). 
Inhibition of Hh activation potently stimulates angiogenesis by the paracrine induction of 
VEGF-A and other angiogenic factors (168), and could therefore account for these 
seemingly disparate observations.  
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The central role of the primary cilium in Hh pathway activation suggests that 
interfering with cilia formation should be an effective strategy for targeting Hh-driven 
tumors. The inhibitory effect of microtubule inhibitors on Hh signaling has been 
demonstrated by unbiased screens that have identified such agents indirectly, as inhibitors 
of GLI activity, or by direct inhibition of cilia formation and function (106, 169, 170). 
Thus far, the antimicrotubule agents identified in these screens are either highly toxic, or 
at early stages of characterization. Our data suggest that MBZ might represent a simple 
path forward for this promising therapeutic strategy.  
A burgeoning body of evidence suggests that Hh signaling is involved in the 
initiation and/or maintenance of a large proportion of human cancers (2, 5, 6, 77). The 
repurposing of MBZ as an anticancer therapeutic will be guided by our rapidly growing 
understanding of the Hh pathway and how it contributes to tumor growth. It will be 
important to understand how MBZ interacts with other agents, including other Hedgehog 
inhibitors. In particular, the additive effect of MBZ on vismodegib that we observed in 
vitro suggests a combinatorial strategy that could potentially alleviate the untoward 
effects associated with vismodegib and also suppress recurrence. Clinical trials will be 
the next step in exploring these new possibilities. 
4.2. PTCH53 as a new component of canonical and noncanonical 
hedgehog pathway 
Our lab’s identification of a novel p53 regulated tumor suppressor gene PTCH53 
provides insight into the molecular links between p53, Hh, and interferon signaling 
pathways. Induced expression of PTCH53 has two consequences: inhibition of canonical 
Hh signaling and activation of interferon response genes. Activation of p53 has been 
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linked to GLI1 inhibition and PTCH53 provides a possible mechanism explaining these 
previously poorly understood findings (171, 172). Loss of p53 activity though mutation 
or deletion has been associated with activated Hh signaling and is always present in 
PTCH1 mutation driven tumors including medulloblastomas (66, 173). The extent of Hh 
regulation through suppression by functional p53 and PTCH53 in non-oncogenic cells is 
an area that requires further research.  
PTCH53 is the first Patched homolog family to be identified as a potential 
regulator of an innate immune response. Whether other PTCH1 homologs share this 
unexpected property is unknown. p53 has been previously established as a transcriptional 
activator of several genes involved in the interferon response pathway including IRF5, 
IRF9 and ISG15, and TLR9 (174-177). Previous reports have also linked interferon 
stimulation to p53 overexpression and stabilization (178, 179). Our findings indicate that 
p53 is an upstream inducer of 15 interferon stimulated genes via PTCH53.  Together this 
information proposes a possible feed forward loop that highlights the necessity of 
functional p53 and PTCH53 for amplification of type 1 interferon response in the innate 
immune targeting of both viral infection and nascent cancer cells (180).  
4.3. Future directions 
Aberrant Hh pathway activation is implicated in a diverse range of cancers, many 
of which have limited treatment options. Therefore, preclinically identifying types of Hh 
driven cancers that are susceptible to MBZ treatment and identifying drugs that can be 




Given the tolerability and efficacy of MBZ, it would be straightforward in 
principle to add it as an additional component to the standard of care for many of the 
cancers associated with Hh activity. Unfortunately, the vast majority of Hh cancers are 
either not amenable to culture in vitro or down regulate their Hh dependence once 
cultured (181). Therefore, there is a lack of suitable models to test MBZ as a Hh 
inhibitor. It will be necessary to use Hh driven cancers with already established in vitro or 
in vivo models that have previously shown successful responses to vismodegib. The four 
models I propose to explore include basal cell carcinoma (BCC), mesothelioma, 
pancreatic cancer, and nevoid basal cell carcinoma (NBCC). 
MBZ may be useful as a chemopreventative agent for individuals with Gorlins 
syndrome. Continuous treatment of low-toxicity Hh inhibitors has been proposed as a 
possible treatment, therefore MBZ offer an affordable, low toxicity, therapeutic option. 
Hh pathway has been identified as a driver of proliferation in malignant pleural 
mesothelioma (MPM) cells (85). Pancreatic cancer cells lines (AsPC-1, PANC-1, MIA 








) all have 
shown dependence on Hh pathway components.(86) Demonstrating the ability of MBZ to 
suppress the Hh activation in NBCC, BCC, MPM and pancreatic cancer may expand the 
therapeutic options for these patients.  
Test MBZ efficacy against additional Hh driven cancers and syndromes.. 
Due to the limited models for studying BCC in vitro, all studies on the cancer will 
all be in vivo. Mice which develop spontaneous BCC tumors have already been 






 mice can be obtained 
upon request.(106) In order to ensure consistency in treatment, established BCC tumors 
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 mice and 
subcutaneously implanted as flank allografts in NOD/SCID mice (0.2 cc/mouse). 5 days 
post implantation; mice will begin receiving treatment in 4 randomized treatment cohorts: 
vehicle, MBZ (50 mg/kg), vismodegib (100mg/kg) and a combination of MBZ and 
vismodegib. Treatment will be administered daily by oral gavage. Flank tumor growth 
will be evaluated by weekly calipers measurement.  Mice will be euthanized when the 
tumors size exceeds justifiable size in accordance with ACUC guidelines. Following 
sacrifice, tumors will be extracted and snap frozen. Transcriptional and translational 
alterations Hh pathway activity will be determined by performing qPCR and 
immunoblotting for Hh markers gli1 and ptch1. Reduction in Hh markers levels and 
reduced tumor proliferation relative to vehicle would indicate successful inhibition of Hh 
driven growth in BCC. This experiment, if successful, should produce sufficient data to 
justify a clinical trial of MBZ in combination with the current standard of care, 
vismodegib. 
To further expand the use of MBZ in Hh driven tumors, an array Hh driven 
malignant pleural mesothelioma cells will be tested (H27373, H245, Gardner, Gates, and 
H513) for inhibited growth and decreased Hh signaling in response to MBZ treatment in 
vitro. Cells will be plated and treated with increasing doses of MBZ in its range of 
therapeutic action (0.1-1uM) for 24 h. Following treatment, RNA will be isolated and 
reverse transcribed to cDNA. Transcriptional changes in the levels of GLI1 and PTCH1 
following MBZ treatment will be assessed by qRT-PCR using vismodegib treated cells as 
a positive control. In conjunction, the effect of MBZ on cell proliferation will be assessed 
on the same array of mesothelioma cells using a standard CellTiter Blue assay. Briefly, 
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cells be seeded in a 96 well plate and treated with MBZ for a total of 96 hours.  
Absorbance readings will be obtained every 24 h to measure changes in cell proliferation 
following drug administration.  The same Hh signaling and viability analysis performed 
in the mesothelioma cells will be replicated in Hh driven pancreatic cancer cell lines 
AsPC-1, PANC-1, MIA PaCa-2. The IC50 of MBZ in each cell line will be determined 
using CellTiter Blue and GLI1 transcript levels will be assessed by qRT-PCR. 
Successfully establishing an in vitro model of MBZ efficacy in Hh inhibition and reduced 
proliferation in melanoma and pancreatic cancer will set the basis for possible future 
clinical trials testing MBZ effect against the cancer in patients. 




 mouse with 
successful spontaneous Hh driven tumors developing in over 90% of the mice (182). 
Once the pups are born and typed, treatment of MBZ will begin at 25 mg/kg/day. In 
addition to survival, the number and size of NBCC tumors presenting on the mice in each 
cohort will be monitored by daily caliper measurements. Whether there is a significant 
correlation between daily MBZ treatment and reduced NBCC emergence will enable us 
to determine if MBZ is a potential preventative agent and if a clinical trial should be 
initiated. 
Increase efficacy of MBZ treatment in Hh cancer via combinatorial treatments 
The effect of MBZ in combination with Hh inhibitors other than vismodegib has 
not been tested. We have already established a functional in vitro screening assay which 
can determine synergy. Any hits will be verified with in vitro and in vivo orthotopic 
models. Even if we identify combinations that are deleterious, it will be an important 
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clinically relevant finding to prevent any patient from ever being prescribed that 
combination in the future.  
We will test for synergy in stages starting with compounds with the highest 
chances of clinical application and FDA approval to the lowest. The initial testing for 
combination therapy will be using and arsenic trioxide. Testing will also be completed in 
the seven current Phase I or II clinical trial candidates, including IPI-926, LDE225, 
LEQ506, PF-04449913, TAK-441, BMS833923, and LY2940680. Further testing may be 
completed among preclinical Hh inhibitor candidates. These compounds target a range of 
components in the Hh pathway including Shh, Smo, LXR, Gli, and Gli2. If any of the 
previous hits render a synergistic combination, we can select preclinical inhibitors that 
function by targeting the same Hh pathway component, to increase the probability of 
finding additional hits.  
Based on our data relating to MBZ mechanism of Hh inhibition, knowing if a 
synergistic compound acts upstream or downstream of Smo would help indicate which 
category of inhibitor target to pursue follow up compounds. Determining synergistic 
combinations will likely lead to greater response in patients and decreased likelihood of 
resistant subclone to either treatment type.  
 Upon identifying the MBZ drug combination with the greatest efficacy, I will 
validate the combined therapy against established human Hh driven medulloblastoma 
model in vitro and in vivo. This will ensure that drug combination not only 
mechanistically inhibits the Hh pathway, but to ensure it translates to reduced 
proliferation in Hh driven cells. Drug combinations will be tested in our established in 
vitro assays for their effect on proliferation, survival, viability, and apoptosis by using 
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BrdU incorporated ELISA, clonogenic assays, CellTiter-Blue, and Hoechst 33258 
staining respectively. All testing in mice will be done with 4 cohorts: vehicle, MBZ 
(50mg/kg), the synergist candidate alone, and combination treatment. Initial testing for 
synergistic or additive combination therapy will be done in a medulloblastoma allograft 




 mouse background (106). The primary in 
vivo testing will be done in a flank, therefore the possibility of synergy will not be 
inhibited by blood brain barrier restriction and will simply be a proof of concept. Effect 
of the treatment on tumor growth will be evaluated by daily measurements of tumor size 
by caliper measurements. Upon sacrifice, tumors will be extracted and snap frozen. At 
the experiments completion, half of each cohort’s tumors will be processed for RNA 
analysis in TRIzol and the other half will be preserved in formalin for subsequent 
processing and staining for relative expression levels of Hh signaling components. 
Inhibition of Hh pathways signaling will be determined by measuring levels of Gli1 and 
Ptch1 by qRT-PCR for each treatment group. Drug combinations which exhibit synergy 
in the flank model will subsequently be tested in the orthotopic medulloblastoma model 
using DAOY cerebellar implantations. This will determine if the drug combination is 
able to extend survival in vivo and will determine if the drug combination will be 
efficacious in this patient population. 
4.4. Summary 
In this dissertation, I evaluated the effects of a drug, MBZ, and a gene, PTCH53, 
on canonical Hh signaling.  MBZ treatment prevented the formation of the primary 
cilium, decreased expression of downstream Hh pathway effectors, and decreased the 
proliferation and survival of human medulloblastoma cells with constitutive Hh 
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activation. Additionally, MBZ inhibited Hh activation in  SMO mutant cells that give rise 
to disease recurrence, and a combination of MBZ and vismodegib achieved additive 
inhibition of SMO. These results support the repurposing of MBZ for use in the many 
types of cancers that are initiated or maintained by active Hh signaling, and suggest 
combinations of drugs that could facilitate the achievement of durable responses. 
PTCH53 is an uncharacterized PTCH1 homolog that is activated by p53. I determined 
that PTCH53 can partially inhibit the canonical Hh pathway. Unexpectedly, PTCH53 
could also upregulate interferon-inducible genes, in an apparent noncanonical pathway. 
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